閉塞性動脈硬化症患者におけるL-カルニチン補充療法の検討

要旨:L-カルニチン投与(900 mg/day,3 カ月間)による閉塞性動脈硬化症患者の自覚症状や運動能への影響を検討した。33 名の検討において疾患特異性の高いVascuQOL 日本語版のactivity ドメインで投与前に比べ3 カ月目に有意差を持って改善が認められた。脈波,AI,6 分間最大歩行距離,WIQ でも改善傾向が認められた。カルニチンは運動能とともに動脈硬化自体も改善する可能性が示唆された。...

Full description

Saved in:
Bibliographic Details
Published in脈管学 Vol. 55; no. 8; pp. 117 - 123
Main Authors 洞口, 哲, 加藤, 盛人, 村上, 厚文
Format Journal Article
LanguageJapanese
Published 日本脈管学会 2015
Subjects
Online AccessGet full text
ISSN0387-1126
1880-8840
DOI10.7133/jca.15-00004

Cover

Abstract 要旨:L-カルニチン投与(900 mg/day,3 カ月間)による閉塞性動脈硬化症患者の自覚症状や運動能への影響を検討した。33 名の検討において疾患特異性の高いVascuQOL 日本語版のactivity ドメインで投与前に比べ3 カ月目に有意差を持って改善が認められた。脈波,AI,6 分間最大歩行距離,WIQ でも改善傾向が認められた。カルニチンは運動能とともに動脈硬化自体も改善する可能性が示唆された。
AbstractList 要旨:L-カルニチン投与(900 mg/day,3 カ月間)による閉塞性動脈硬化症患者の自覚症状や運動能への影響を検討した。33 名の検討において疾患特異性の高いVascuQOL 日本語版のactivity ドメインで投与前に比べ3 カ月目に有意差を持って改善が認められた。脈波,AI,6 分間最大歩行距離,WIQ でも改善傾向が認められた。カルニチンは運動能とともに動脈硬化自体も改善する可能性が示唆された。
Author 洞口, 哲
加藤, 盛人
村上, 厚文
Author_xml – sequence: 1
  fullname: 洞口, 哲
  organization: 国際医療福祉大学病院循環器センター血管外科
– sequence: 1
  fullname: 加藤, 盛人
  organization: 国際医療福祉大学病院循環器センター血管外科
– sequence: 1
  fullname: 村上, 厚文
  organization: 国際医療福祉大学病院循環器センター血管外科
BookMark eNo9UEtLw0AYXKSCtfbm30jdVzaboxZfUNCDnpdNutGGWiXpxVuTWqpWBA-tCEUoFRQqXvqTlqTxXxgfOAwzhxk-PmYVFFrnLQXAOoIVCxGy4buygkwD5qBLoIg4hwbnFBZAERJuGQhhtgLKYdhw8opNIbGtIjj8HN0kk-e085oMhtnV9WLyntyNFo_9NJ5mnZ6OZjq61dGDjgc1Q8cz3c050N1Id-fZdJz0eounOJ0PdfSRvoyzt_s1sOzJZqjKf14CxzvbR9U9o3awu1_drBk-hkwa3CG8zghxiKIIOraFqQ0JzX9ktqNcijwPMoRt6LmUYcUYRtyrQ-zVKUGIK1ICW793_bAtT5S4CBpnMrgUMmg33KYS-RzCNAX_FmSKn1n-Q_dUBsKX5AsDZ3VD
ContentType Journal Article
Copyright 2015 日本脈管学会
Copyright_xml – notice: 2015 日本脈管学会
DOI 10.7133/jca.15-00004
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 1880-8840
EndPage 123
ExternalDocumentID article_jca_55_8_55_15_00004_article_char_ja
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
GROUPED_DOAJ
JSF
KQ8
RJT
ID FETCH-LOGICAL-j206a-8b38d633b3e410b9724903412669bec41ff061290fc462e66218fd02fd43118e3
ISSN 0387-1126
IngestDate Wed Sep 03 06:23:08 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language Japanese
License https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j206a-8b38d633b3e410b9724903412669bec41ff061290fc462e66218fd02fd43118e3
OpenAccessLink https://www.jstage.jst.go.jp/article/jca/55/8/55_15-00004/_article/-char/ja
PageCount 7
ParticipantIDs jstage_primary_article_jca_55_8_55_15_00004_article_char_ja
PublicationCentury 2000
PublicationDate 2015
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – year: 2015
  text: 2015
PublicationDecade 2010
PublicationTitle 脈管学
PublicationTitleAlternate 脈管学
PublicationYear 2015
Publisher 日本脈管学会
Publisher_xml – name: 日本脈管学会
References 13) 児玉浩子,清水俊明,瀧谷公隆,他:特殊ミルク,経腸栄養剤使用時のピットフォール.日本小児科学会誌2012; 116: 637–653
1) Brevetti G, Diehm C, Lambert D: European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618–1624
5) 池田俊也,小林亜美,重松博,他:日本語版WIQ(歩行障害質問票)の開発.2005; 45: 233–240
10) Brevetti G, di Lisa F, Perna S, et al: Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation 1996; 93: 1685–1689
2) Hiatt WR, Regensteiner JG, Creager MA, et al: Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110: 616–622
3) Norgren L, Hiatt WR, Dormandy JA, et al: Inter-society concensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S1–S67
11) Nakajima Y, Ito T, Maeda Y, et al: Detection of pivaloylcarnitine in pediatric patients with hypocarnitinemia after long-term administration of pivalate-containing antibiotics. Tohoku J Exp Med 2010; 221: 309–313
4) 南都伸介,飯田修:閉塞性動脈硬化症(PAD)診療の実践.PAD の病態生理―間欠性跛行を中心に,南江堂,東京,2009,1–5
9) Stephens FB, Constantin-Teodosiu D, Laithwaite D, et al: An Acute Increase in skeltal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J Clin Endocrinol 2006; 91: 5013–5018
18) Brevetti G, Chiariello M, Ferulano G, et al: Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767–773
6) 山口拓洋,宮田哲郎,市来正孝,他:VascuQOL の信頼性と妥当性の検討.脈管学 2011; 51: 347–358
15) Brevetti G, Perna S, Sabbà C, et al: Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251–255
7) Eguchi K, Murakami A, Horaguchi T, et al: Percutaneous transluminal angioplasty for peripheral artery disease confers cardiorenal protection. J Human Hypertens 2013; 37: 1–5
20) Higuchi T, Abe M, Yamazaki T, et al: Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial. Nutrients 2014; 6: 5992–6004
8) 高柳正樹:カルニチンの臨床.生物試料分析 2012; 35: 281–292
14) 田附裕子,曹英樹,上野豪久,他:中心静脈栄養施行患者におけるカルニチン補充の必要性の検討.静脈経腸栄養 2010; 25: 210
17) Brevetti G, Angelini C, Rosa M, et al: Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84: 1490–1495
16) Hiatt WR, Wolffl EE, Regensteiner JG, et al: Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. Am J Physiol 1992; 73: 346–353
19) Goldenberg NA, Krantz MJ, Hiatt WR: L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med 2012; 17: 145–154
12) Matsuda I, Ohtani Y, Ninomiya N: Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 1986; 109: 131–134
References_xml – reference: 19) Goldenberg NA, Krantz MJ, Hiatt WR: L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Vasc Med 2012; 17: 145–154
– reference: 5) 池田俊也,小林亜美,重松博,他:日本語版WIQ(歩行障害質問票)の開発.2005; 45: 233–240
– reference: 16) Hiatt WR, Wolffl EE, Regensteiner JG, et al: Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease. Am J Physiol 1992; 73: 346–353
– reference: 20) Higuchi T, Abe M, Yamazaki T, et al: Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial. Nutrients 2014; 6: 5992–6004
– reference: 6) 山口拓洋,宮田哲郎,市来正孝,他:VascuQOL の信頼性と妥当性の検討.脈管学 2011; 51: 347–358
– reference: 8) 高柳正樹:カルニチンの臨床.生物試料分析 2012; 35: 281–292
– reference: 17) Brevetti G, Angelini C, Rosa M, et al: Muscle carnitine deficiency in patients with severe peripheral vascular disease. Circulation 1991; 84: 1490–1495
– reference: 12) Matsuda I, Ohtani Y, Ninomiya N: Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy. J Pediatr 1986; 109: 131–134
– reference: 11) Nakajima Y, Ito T, Maeda Y, et al: Detection of pivaloylcarnitine in pediatric patients with hypocarnitinemia after long-term administration of pivalate-containing antibiotics. Tohoku J Exp Med 2010; 221: 309–313
– reference: 1) Brevetti G, Diehm C, Lambert D: European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34: 1618–1624
– reference: 15) Brevetti G, Perna S, Sabbà C, et al: Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13: 251–255
– reference: 2) Hiatt WR, Regensteiner JG, Creager MA, et al: Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110: 616–622
– reference: 7) Eguchi K, Murakami A, Horaguchi T, et al: Percutaneous transluminal angioplasty for peripheral artery disease confers cardiorenal protection. J Human Hypertens 2013; 37: 1–5
– reference: 10) Brevetti G, di Lisa F, Perna S, et al: Carnitine-related alterations in patients with intermittent claudication: indication for a focused carnitine therapy. Circulation 1996; 93: 1685–1689
– reference: 3) Norgren L, Hiatt WR, Dormandy JA, et al: Inter-society concensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S1–S67
– reference: 14) 田附裕子,曹英樹,上野豪久,他:中心静脈栄養施行患者におけるカルニチン補充の必要性の検討.静脈経腸栄養 2010; 25: 210
– reference: 9) Stephens FB, Constantin-Teodosiu D, Laithwaite D, et al: An Acute Increase in skeltal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J Clin Endocrinol 2006; 91: 5013–5018
– reference: 13) 児玉浩子,清水俊明,瀧谷公隆,他:特殊ミルク,経腸栄養剤使用時のピットフォール.日本小児科学会誌2012; 116: 637–653
– reference: 18) Brevetti G, Chiariello M, Ferulano G, et al: Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation 1988; 77: 767–773
– reference: 4) 南都伸介,飯田修:閉塞性動脈硬化症(PAD)診療の実践.PAD の病態生理―間欠性跛行を中心に,南江堂,東京,2009,1–5
SSID ssib000940397
ssib005879700
ssib051641554
ssj0002920462
ssib002227066
ssib058493671
ssib050995460
Score 1.9796745
Snippet 要旨:L-カルニチン投与(900 mg/day,3 カ月間)による閉塞性動脈硬化症患者の自覚症状や運動能への影響を検討した。33 名の検討において疾患特異性の高いVascuQOL 日本語版のactivity ドメインで投与前に比べ3 カ月目に有意差を持って改善が認められた。脈波,AI,6 分間最大歩行距離,WIQ...
SourceID jstage
SourceType Publisher
StartPage 117
SubjectTerms arteriosclerosis obliterans
carnitine
treadmill performance
VascuQOL (activity domain)
WIQ
Title 閉塞性動脈硬化症患者におけるL-カルニチン補充療法の検討
URI https://www.jstage.jst.go.jp/article/jca/55/8/55_15-00004/_article/-char/ja
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 脈管学, 2015, Vol.55(8), pp.117-123
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1NaxQxdKj14kUUFb_pwRynzkcySfCU3U4p0oqHFnobdmYnhz1Uke2hHqS7tfixInhoRShCqaBQ8dKfNOyH_8L3ktndURSswhDeJi_vzXsvM3kvm5dxnDtCskzg0ptmWeBSThtug-vUzXhKaQohSWhyq1YeREtr9P46W585s1XZtbTZTuezp7_NK_kXq0Id2BWzZE9h2QlRqAAY7AslWBjKv7IxiSWRERGSxIwon8iYxBHuXVAca0SNSEZiQQQ4jILEHHFU3TTVsSPUSE4EN70CokKD7BEBvULwMYmqlYBQJSB9AwRAfNktwRIrnAJiAvglUDO0gYO0_M2F_CVSAP6AICdsjRyKGmToBTcVV73on2WKUSxUwAJRk3VGQ5IajQCrReQMgwl_SLiZYIrGUDblIUnQBfA0aHBjNbxiSmqKTBczkKxcMFqAFoF9S7IiJlKZZtAlry6m2ERSM_BNO3BhBqgbY_xRFMMC7KQqL2s8oxjTsey8aicTeDe6QtjjqMazjT2UuHyqRGXq8G0Oa-mF-DYL-9cJDpcUcILLGvM-c02AN53IJ9srywGZAFrCWCKw8Fli0JNxI2b1JS0ILc4GnPu4G3blWVzxvKkXymqkH_Dqwf9McFk52RHcTsnoNNJmEIVXPVVwc2U4PkkRnST8SBqN7H98peZsWgpKeLcqH7iGLQiUxpssjd-3esE5XwZsc8rKc9GZaTUuOQ-_77_qH34cbH_u9_ZGz18OD7_23-wP378YdI9G27tF57jovC4674pub9ktusfFDly9YqdT7JyMjg76u7vDD93ByV7R-Tb4dDD68vays7YYr9aX3PLbJG4r8KKGK9JQNKMwTMOc-l4qeUClBx4h-LsSXovU1xqDB-npDMTMowhcad30At0Ej90XeXjFmd14tJFfdebSXDPu04w1oKQ6FKC5vJly7mnNpNbXnHtWAcljewBNchr7Xv-v3jecc_iY2DXHm85s-8lmfgu88HZ624yXH6DYsrw
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E9%96%89%E5%A1%9E%E6%80%A7%E5%8B%95%E8%84%88%E7%A1%AC%E5%8C%96%E7%97%87%E6%82%A3%E8%80%85%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8BL-%E3%82%AB%E3%83%AB%E3%83%8B%E3%83%81%E3%83%B3%E8%A3%9C%E5%85%85%E7%99%82%E6%B3%95%E3%81%AE%E6%A4%9C%E8%A8%8E&rft.jtitle=%E8%84%88%E7%AE%A1%E5%AD%A6&rft.au=%E6%B4%9E%E5%8F%A3%2C+%E5%93%B2&rft.au=%E5%8A%A0%E8%97%A4%2C+%E7%9B%9B%E4%BA%BA&rft.au=%E6%9D%91%E4%B8%8A%2C+%E5%8E%9A%E6%96%87&rft.date=2015&rft.pub=%E6%97%A5%E6%9C%AC%E8%84%88%E7%AE%A1%E5%AD%A6%E4%BC%9A&rft.issn=0387-1126&rft.eissn=1880-8840&rft.volume=55&rft.issue=8&rft.spage=117&rft.epage=123&rft_id=info:doi/10.7133%2Fjca.15-00004&rft.externalDocID=article_jca_55_8_55_15_00004_article_char_ja
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0387-1126&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0387-1126&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0387-1126&client=summon